Ezetimibe prevents the development of non-alcoholic fatty liver disease induced by high-fat diet in C57BL/6J mice

There is currently no established treatment for non-alcoholic fatty liver disease (NAFLD), including its most extreme form, non-alcoholic steatohepatitis (NASH). Ezetimibe, an inhibitor of Niemann-Pick C1 Like 1-dependent cholesterol absorption, improves diet-induced hyperlipidemia and attenuates li...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular medicine reports 2014-12, Vol.10 (6), p.2917-2923
Hauptverfasser:	WANG, XIANG, REN, QIAOHUA, WU, TAO, GUO, YONG, LIANG, YONG, LIU, SUBO
Format:	Artikel
Sprache:	eng
Schlagworte:	Acetyl-CoA Carboxylase - metabolism Animals Anticholesteremic Agents - pharmacology Azetidines - pharmacology Cancer Causes of CD36 antigen CD36 Antigens - metabolism Cell cycle Cholesterol Complications and side effects Diabetes Diet Diet, High-Fat - adverse effects Drug therapy Ezetimibe Fasting Fatty acids Fatty Acids - metabolism Fatty liver Fibrosis Fibrosis - metabolism Gene expression hepatocellular carcinoma High fat diet Hyperinsulinemia Hyperinsulinism - metabolism Hyperlipidemia Insulin Insulin resistance Insulin Resistance - physiology Ketogenic diet Laboratory animals Lipid Metabolism - drug effects Lipogenesis - drug effects Liver cancer Liver diseases liver steatosis Male Metabolic syndrome Mice Mice, Inbred C57BL Niemann-Pick disease non-alcoholic fatty liver disease Non-alcoholic Fatty Liver Disease - metabolism Non-alcoholic Fatty Liver Disease - prevention & control Obesity Phase transitions Physiological aspects Protein expression Proteins Rodents Stearoyl-CoA Desaturase - metabolism Steatosis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!